Patent US20040148019A1 successfully refreshed from Google Patents.
US5316766A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Thrombosis treatment with fibrinolytics and prostacyclins
Assignee: Bayer Pharma AG
•
Filing: 1990-02-06
•
Granted: 1994-05-31
•
Expires: 2010-02-06
Abstract
Abstract The combination of a fibrinolytic and a prostacyclin analogue is very useful for thrombosis treatment, especially to avoid subsequent rethrombosis.
Inventors
- 👤 Berthold Baldus
- 👤 Bernhard Maass
- 👤 Bernd Muller
- 👤 Werner Witt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:22
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
26 words
A pharmaceutical composition useful for thrombosis treatment comprising an effective amount of a fibrinolytic agent and an amount of a carbacyclin effective to inhibit thrombocyte aggregation.
Claim 2
Dependent Claim
26 words
A pharmaceutical composition useful for thrombosis treatment comprising an effective amount of a fibrinolytic agent and an amount of a carbacyclin effective to inhibit thrombocyte aggregation.
Claim 3
Dependent Claim
11 words
A composition of claim 1, wherein the fibrinolytic agent is streptokinase.
Claim 4
Dependent Claim
10 words
A composition of claim 2, wherein the carbacyclin is Iloprost.
Claim 5
Dependent Claim
11 words
A composition of claim 2, wherein the carbacyclin is 5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6-[(3S,4S)-3-hydroxy-4-methyl-nona-1,6-diinyl]-bicyclo[3.3.0]octan-3-ylidene}-3-oxapentanoic acid.
Claim 6
Dependent Claim
29 words
A pharmaceutical composition useful for thrombosis treatment comprising an effective amount of a fibrinolytic agent which is t-PA and an amount of a carbacyclin effective to inhibit thrombocyte aggregation.
Claim 7
Dependent Claim
29 words
A pharmaceutical composition useful for thrombosis treatment comprising an effective amount of a fibrinolytic agent which is t-PA and an amount of a carbacyclin effective to inhibit thrombocyte aggregation.
Claim 8
Dependent Claim
15 words
A composition of claim 1, wherein the fibrinolytic agent is urokinase, pro-urokinase or pro t-PA.
Claim 9
Dependent Claim
10 words
A composition of claim 1, wherein the carbacyclin is Iloprost.
Claim 10
Dependent Claim
17 words
A composition of claim 1, wherein the carbacyclin is (5E)-(16RS)-13,14-didehydro-16,20-dimethyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin-I 2 , (5E)-(16RS)-13,14-didehydro,1a,1b-dihomo-16,20-dimethyl-3-oxa-18,18,19,19-tetradehydro-6a-carbaprostaglandin-I 2 or 5-(E)-{1S,5S,6S,7R)-7-hydroxy-6-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diinyl]-bicyclo[[3.3.0]octan-3-ylidene}-3-oxapentanoic acid.
Claim 11
Dependent Claim
11 words
A composition of claim 1, wherein the carbacyclin is 5-{(E)-(1S,5S,6S,7R)-7-hydroxy-6-[(3S,4S)-3-hydroxy-4-methyl-nona-1,6-diinyl]-bicyclo[3.3.0]octan-3-ylidene}-3-oxapentanoic acid.
Claim 12
Dependent Claim
22 words
A composition of claim 1, wherein the weight ratio of fibrinolytic agent to carbacyclin is 10 7 :1 to 10 2 :1.
Claim 13
Dependent Claim
26 words
A composition of claim 1, wherein the amount of carbacyclin is 10 ng to 1 mg of Iloprost or a biologically equivalent amount of another carbacyclin.
Claim 14
Dependent Claim
29 words
A composition of claim 1, wherein the amount of fibrinolytic agent is 5000 IU to 1 million IU of streptokinase or a biologically equivalent amount of another fibrinolytic agent.
Claim 15
Dependent Claim
57 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of the composition of claim 1 to the patient, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 16
Dependent Claim
57 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of the composition of claim 2 to the patient, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 17
Dependent Claim
10 words
A combination of claim 5, wherein the carbacyclin is iloprost.
Claim 18
Dependent Claim
57 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of the composition of claim 5 to the patient, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 19
Dependent Claim
57 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of the composition of claim 7 to the patient, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 20
Dependent Claim
57 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of the composition of claim 8 to the patient, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 21
Dependent Claim
57 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of the composition of claim 3 to the patient, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 22
Independent Claim
59 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of a carbacyclin and an effective amount of a fibrinolytic agent, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 23
Independent Claim
59 words
A method of treating thrombosis while reducing or preventing the risk of rethrombosis in a patient in need of such treatment, comprising administering an effective amount of a carbacyclin and an effective amount of a fibrinolytic agent, whereby the extent of rethrombosis occurring after said administration is reduced in comparison to that occurring after administration of the fibrinolytic alone.
Claim 24
Dependent Claim
16 words
A method of claim 20, wherein the administration of the tPA and the carbacyclin is simultaneously.
Claim 25
Dependent Claim
16 words
A method of claim 20, wherein the administration of the tPA and the carbacyclin is sequential.
Claim 26
Independent Claim
37 words
A method of reducing or preventing the risk of rethrombosis in a patient receiving or having received treatment for thrombosis comprising administering to said patient an amount of a carbacyclin effective to inhibit the aggregation of thrombocytes.
Claim 27
Independent Claim
37 words
A method of reducing or preventing the risk of rethrombosis in a patient receiving or having received treatment for thrombosis comprising administering to said patient an amount of a carbacyclin effective to inhibit the aggregation of thrombocytes.
Claim 28
Dependent Claim
34 words
A kit comprising an effective amount of a fibrinolytic agent and an amount of a carbacyclin effective to inhibit thrombocyte aggregation, wherein the fibrinolytic agent and the carbacyclin are present in separate dosage units.
Claim 29
Dependent Claim
34 words
A kit comprising an effective amount of a fibrinolytic agent and an amount of a carbacyclin effective to inhibit thrombocyte aggregation, wherein the fibrinolytic agent and the carbacyclin are present in separate dosage units.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-05-30 | 1997-11-29 | 1998-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-05-30 | 2001-11-29 | 2002-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-05-30 | 2005-11-29 | 2006-05-31 | $7700.00 | Window Closed / Lapsed |